The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
Documentos PDF
Imagenes y Videos
Abstract
Coronavirus disease 2019 (COVID
-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS
-CoV-2), is currently defined as the worst pandemic disease.
SARS
-CoV-2 infects human cells via the binding of its S protein to the receptor
angiotensin
-converting enzyme (ACE2). The use of ACEIs/ARBs (RAAS inhibitors)
regulates the renin
-angiotensin
-aldosterone system (RAAS) and may increase ACE2
expression. Considering the large use of ACEIs/ARBs in hypertensive patients, some
professional groups are concerned about whether the use of RAAS inhibitors affects
the risk of SARS
-CoV-2 infection or the risk of severe illness and mortality in
COVID
-19 patients. In this review, we summarize preclinical and clinical studies to
investigate whether the use of ACEIs/ARBs increases ACE2 expression in animals or
patients. We also analyzed whether the use of these drugs affects the risk of
SARS
-CoV-2 infection, severe illness or mortality based on recent studies. Finally,
the review suggests that current evidence does not support the concerns.
Palabras clave
COVID -19; RAAS inhibitor; ACE2; SARS -CoV-2Link to resource
https://doi.org/10.1016/j.lfs.2020.118142Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.